News Review: TransEnterix Inc (NYSE: TRXC)

On Wednesday, Shares of TransEnterix Inc (NYSE: TRXC) declined -4.24% to $3.84. The stock recorded $3.72 as its minimum price and hit the max level of $4.04, during its most recent trading session. It traded total volume of 7.99M shares higher than the average volume of 5.99M shares.

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, recently declared its operating and financial results for the first quarter 2018.

First Quarter Financial Highlights:

For the three months ended March 31, 2023, the Company stated revenue of $4.80M as contrast to revenue of $1.90M in the three months ended March 31, 2017. Revenue in the first quarter of 2018 included $3.50M in system sales, $1.10M in instruments and accessories, and $200.0K in services.

For the three months ended March 31, 2023, total net operating income and expenses were $5.40M, as contrast to $16.50M in the three months ended March 31, 2017.

For the three months ended March 31, 2023, net loss was $0.90M, or $0.00 per share, as contrast to a net loss of $15.40M, or $0.13 per share, in the three months ended March 31, 2017.

For the three months ended March 31, 2023, adjusted net loss was $11.30M, or $0.06 per share, as contrast to an adjusted net loss of $12.60M, or $0.11 per share in the three months ended March 31, 2017, after adjusting for the gain from the sale of SurgiBot assets and non-cash charges for amortization of intangible assets, change in fair value of contingent consideration, and change in fair value of warrant liabilities.

TRXC has the market capitalization of $1.05B and its EPS growth ratio for the past five years was 41.60%. The return on assets ratio of the Company was -60.20% while its return on investment ratio stands at -30.50%. Price to sales ratio was 105.97 while 26.00% of the stock was owned by institutional investors.